Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNASDAQ:DNTHNASDAQ:KALVNYSE:VCXB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.87+10.6%$5.73$2.90▼$11.16$283.87M0.583.24 million shs19.03 million shsDNTHDianthus Therapeutics$18.63+5.7%$19.09$13.37▼$32.27$566.98M1.37263,280 shs346,766 shsKALVKalVista Pharmaceuticals$11.31-0.9%$12.46$7.30▼$15.50$567.26M-0.01486,228 shs776,963 shsVCXB10X Capital Venture Acquisition Corp. III$11.07$11.05$10.48▼$12.99$146.01M0.0743,760 shs16,992 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%-50.34%-35.54%-30.00%-47.37%DNTHDianthus Therapeutics0.00%+4.63%+1.21%-2.81%-31.88%KALVKalVista Pharmaceuticals0.00%-6.09%-2.98%-1.13%-3.14%VCXB10X Capital Venture Acquisition Corp. III0.00%0.00%0.00%0.00%+0.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.2736 of 5 stars3.51.00.00.02.91.70.6DNTHDianthus Therapeutics1.6262 of 5 stars3.60.00.00.02.71.70.0KALVKalVista Pharmaceuticals4.2149 of 5 stars3.61.00.04.43.12.50.6VCXB10X Capital Venture Acquisition Corp. IIIN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 3.00Buy$19.00390.96% UpsideDNTHDianthus Therapeutics 3.14Buy$53.00184.49% UpsideKALVKalVista Pharmaceuticals 3.13Buy$24.83119.57% UpsideVCXB10X Capital Venture Acquisition Corp. III 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VCXB, DNTH, ALT, and KALV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/13/2025DNTHDianthus TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $50.005/13/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.004/8/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K15,694.79N/AN/A$1.74 per share2.22DNTHDianthus Therapeutics$6.24M96.02N/AN/A$11.91 per share1.56KALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.86 per shareN/AVCXB10X Capital Venture Acquisition Corp. IIIN/AN/A$0.06 per share176.88($1.49) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.260.00N/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)DNTHDianthus Therapeutics-$84.97M-$2.880.00N/AN/A-1,544.23%-29.26%-27.87%8/6/2025 (Estimated)KALVKalVista Pharmaceuticals-$126.64M-$3.72N/AN/AN/AN/A-104.25%-78.69%7/10/2025 (Estimated)VCXB10X Capital Venture Acquisition Corp. III$700KN/A0.00∞N/AN/AN/AN/AN/ALatest VCXB, DNTH, ALT, and KALV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/10/2025Q4 2025KALVKalVista Pharmaceuticals-$0.83N/AN/AN/AN/AN/A5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million5/12/2025Q1 2025DNTHDianthus Therapeutics-$0.86-$0.82+$0.04-$0.82$0.81 million$1.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AVCXB10X Capital Venture Acquisition Corp. IIIN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A15.8515.85DNTHDianthus TherapeuticsN/A15.9815.99KALVKalVista PharmaceuticalsN/A10.4410.44VCXB10X Capital Venture Acquisition Corp. IIIN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%DNTHDianthus Therapeutics47.53%KALVKalVista PharmaceuticalsN/AVCXB10X Capital Venture Acquisition Corp. III13.25%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%DNTHDianthus Therapeutics16.56%KALVKalVista Pharmaceuticals10.50%VCXB10X Capital Venture Acquisition Corp. III82.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million77.78 millionOptionableDNTHDianthus Therapeutics8032.16 million26.83 millionOptionableKALVKalVista Pharmaceuticals10049.72 million44.50 millionOptionableVCXB10X Capital Venture Acquisition Corp. III413.19 million2.31 millionNot OptionableVCXB, DNTH, ALT, and KALV HeadlinesRecent News About These Companies10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-K FilingApril 23, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeTop 3 Silver Picks to Watch as Bull Market Gains SteamBy Chris Markoch | June 18, 2025View Top 3 Silver Picks to Watch as Bull Market Gains SteamHims & Hers Stock: Buy the Dip or Wait It Out?By Gabriel Osorio-Mazilli | June 5, 2025View Hims & Hers Stock: Buy the Dip or Wait It Out?UnitedHealth Stock Dips: Is This a Value Buy Opportunity?By Jeffrey Neal Johnson | June 13, 2025View UnitedHealth Stock Dips: Is This a Value Buy Opportunity?Apple’s Quiet HomePad Delay Could Be Its Loudest Move YetBy Chris Markoch | June 1, 2025View Apple’s Quiet HomePad Delay Could Be Its Loudest Move YetVCXB, DNTH, ALT, and KALV Company DescriptionsAltimmune NASDAQ:ALT$3.87 +0.37 (+10.57%) As of 04:00 PM EasternAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Dianthus Therapeutics NASDAQ:DNTH$18.63 +1.00 (+5.67%) As of 04:00 PM EasternDianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.KalVista Pharmaceuticals NASDAQ:KALV$11.31 -0.10 (-0.88%) As of 04:00 PM EasternKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.10X Capital Venture Acquisition Corp. III NYSE:VCXB10X Capital Venture Acquisition Corp. III does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to identify business opportunities in the field of consumer internet, e-commerce, software, healthcare, transportation/mobility, financial services, artificial intelligence, automation, data science, and Software-as-a-Service. The company was incorporated in 2021 and is based in New York, New York. 10X Capital Venture Acquisition Corp. III operates as a subsidiary of 10X Capital SPAC Sponsor III LLC. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
